NCT03649724View on ClinicalTrials.gov

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions
Alzheimer DiseaseMild Cognitive Impairment
Interventions
DRUG

Placebo

Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.

DRUG

Eligard 22.5Mg Suspension for Injection

Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.

Trial Locations (3)

10021

Weill Medical College of Cornell University, New York

33433

University of Miami Miller School of Medicine, Boca Raton

53792

University of Wisconsin - Madison, Madison

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Tolmar Pharmaceuticals

UNKNOWN

lead

Weill Medical College of Cornell University

OTHER